Featured news from NHIVNA
HIV-related news from NAM
Disappointing result for tenofovir-gel microbicide shows that young women still lack HIV prevention methods they can use
Gus Cairns, 2015-02-25 07:00:00
Among some highly promising results from HIV prevention
studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, today, there was one disappointment.
FACTS 001, a study testing the efficacy against HIV of a vaginal microbicide
gel containing tenofovir, produced a null result: there was no difference in
the HIV infection rate in young women given the gel and the rate in young women
given a placebo gel.
Among the 2029 women in the study allocated to either
tenofovir or placebo gel, there were 61 infections in women using tenofovir gel
and 62 in women using placebo. This was equivalent to an annual incidence rate
of 4% (close to the 3.5% the researchers anticipated).